Medical Doctor Program year 2021 Reported 2019–2021 Source: CMS Open Payments, 2026 publication

Susan Youngs

Pediatric Rehabilitation Medicine Dearborn, MI Medical Doctor

NPI 1801865183 CMS profile 217413

18501 Rotunda Dr Ste 200, Dearborn, MI 48124

Open in the dashboard

General payments

$319

13 records reported · program years 2019–2021

Research payments

$0

Paid to them · None reported · program years 2019–2021

Ownership & investment interest

$0

None reported

Through program year 2021, Susan Youngs of Dearborn, MI is reported in the CMS Open Payments database as having received $319 across 13 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Pediatric Rehabilitation Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2021 General $15 1
2020 General $60 2
2019 General $244 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Susan Youngs
  • Pediatric Rehabilitation Medicine median
  • Middle half of Pediatric Rehabilitation Medicine
  • National median

In program year 2025, general payments to Susan Youngs were reported at $0. Among 99 Pediatric Rehabilitation Medicine profiles paid that year, the median was $109 and the middle half received between $35 and $182.

Show as a table
Year Susan Youngs Pediatric Rehabilitation Medicine median Middle half National median
2019 $244 $160 $37–$360 $163
2020 $60 $60 $16–$181 $114
2021 $15 $108 $31–$499 $132
2022 $0 $96 $36–$215 $149
2023 $0 $101 $29–$293 $160
2024 $0 $77 $26–$150 $164
2025 $0 $109 $35–$182 $169

Breakdown

Who paid General payments · program years 2019–2021
  1. Ipsen Biopharmaceuticals, Inc $115 1 payment
  2. Saol Therapeutics Inc. $86 4 payments
  3. Neos Therapeutics, LP $30 2 payments
  4. Allergan Inc. $29 2 payments
  5. Biogen, Inc. $20 1 payment
  6. Supernus Pharmaceuticals, Inc. $15 1 payment
  7. Tris Pharma Inc $13 1 payment
  8. Arbor Pharmaceuticals, Inc. $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2021
  1. Food and Beverage $259 11 payments
  2. Gift $60 2 payments
Products named General payments · program years 2019–2021
  1. DYSPORT Neurology $115 1 payment
  2. LIORESAL (BACLOFEN) $86 4 payments
  3. COTEMPLA XR-ODT $30 2 payments
  4. Adzenys XR-ODT $30 2 payments
  5. BOTOX $29 2 payments
  6. SPINRAZA $20 1 payment
  7. QELBREE $15 1 payment
  8. Dysport Spasticity $14 1 payment
  9. Dyanavel XR $13 1 payment
  10. Edarbi $12 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

258

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$14,129

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

19%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Paliperidone Er Paliperidone Brand 22 $8,142
Methylphenidate Er Methylphenidate Hcl Brand 13 $3,114
Guanfacine Hcl Er Guanfacine Hcl Brand 14 $790
Trazodone Hcl Generic 46 $584
Aripiprazole Generic 11 $512
Sertraline Hcl Generic 55 $252
Hydroxyzine Hcl Generic 13 $182
Lorazepam Generic 15 $132
Clonazepam Generic 13 $126
Clonidine Hcl Generic 34 $123

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$1,971

Medicare's payments for the services billed

Medicare patients

27

Average age 29

Services billed

35

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Ischemic heart disease 0%
Cancer 0%
Osteoporosis 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

13 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Rehabilitation Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2021

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record